Evidence map›Paper›PMID 32434932›Full record

Trial reportBMJ open2020

Vaginal probiotic adherence and acceptability in Rwandan women with high sexual risk participating in a pilot randomised controlled trial: a mixed-methods approach.

Marijn C Verwijs, Stephen Agaba, Marie Michele Umulisa, Mireille Uwineza, Adrien Nivoliez, Elke Lievens, Janneke H H M van de Wijgert

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMJ open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02459665 (Preparing for a Clinical Trial of Interventions to Maintain Normal Vaginal Microbiota for Preventing Adverse Reproductive Health Outcomes in Africa), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02459665 nacompletednot on this map

Preparing for a Clinical Trial of Interventions to Maintain Normal Vaginal Microbiota for Preventing Adverse Reproductive Health Outcomes in Africa

TypeinterventionalSponsorJanneke van de WijgertRan2015 to 2018Enrolled68ConditionsBacterial VaginosisArmsVaginal multiple lactobacilli-containing probiotic for prevention of BV recurrence, Prophylactic use of metronidazole pills (500 mg), Vaginal Lcr35-containing probiotic for prevention of BV recurrence
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Acceptability of the live biotherapeutic LACTIN-V (Frontiers in reproductive health · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Marijn C VerwijsDepartment of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, Liverpool, Merseyside, UK.ORCID 0000-0002-7745-5148
Stephen AgabaRinda Ubuzima, Kigali, Rwanda.
Marie Michele UmulisaRinda Ubuzima, Kigali, Rwanda.
Mireille UwinezaRinda Ubuzima, Kigali, Rwanda.
Adrien NivoliezBiose, Aurillac, France.
Elke LievensWinclove, Amsterdam, The Netherlands.
Janneke H H M van de WijgertDepartment of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, Liverpool, Merseyside, UK j.vandewijgert@liverpool.ac.uk.ORCID 0000-0003-2728-4560
University of Liverpool · GBWinclove Probiotics (Netherlands) · NL

Funding

Medical Research Council MR/M017443/1Wellcome Trust
6 · The paper itself

Abstract

objectivesTo evaluate adherence and acceptability of intermittent vaginal probiotic or antibiotic use to prevent bacterial vaginosis (BV) recurrence.

designRepeated adherence and acceptability assessments using mixed methods within a pilot randomised controlled trial.

settingResearch clinic in Kigali, Rwanda.

participantsRwandan women with high sexual risk.

interventionsWomen diagnosed with BV and/or trichomoniasis were randomised to four groups (n=17 each) after completing metronidazole treatment: behavioural counselling only, or behavioural counselling plus 2-month intermittent use of oral metronidazole, Ecologic Femi+ (EF+) vaginal capsule or Gynophilus LP (GynLP) vaginal tablet. OUTCOME MEASURES: Adherence and acceptability were assessed by structured face-to-face interviews, semi-structured focus group discussions and in-depth interviews, daily diaries and counting of used/unused study products in randomised women (n=68). Vaginal infection knowledge was assessed by structured face-to-face interviews in randomised women and women attending recruitment sessions (n=131).

resultsMost women (93%) were sex workers, 99.2% were unfamiliar with BV and none had ever used probiotics. All probiotic users (n=32) reported that insertion became easier over time. Triangulated adherence data showed that 17/17 EF+ users and 13/16 GynLP users used ≥80% of required doses (Fisher's exact p=0.103). Younger age (p=0.076), asking many questions at enrolment (p=0.116), having menses (p=0.104) and reporting urogenital symptoms (p=0.103) were non-significantly associated with lower perfect adherence. Women believed that the probiotics reduced BV recurrence, but reported that partners were sometimes unsupportive of study participation. Self-reported vaginal washing practices decreased during follow-up, but sexual risk behaviours did not. Most women (12/15) with an uncircumcised steady partner discussed penile hygiene with him, but many women found this difficult, especially with male clients.

conclusionsHigh-risk women require education about vaginal infections. Vaginal probiotic acceptability and adherence were high in this cohort. Our results can be used to inform future product development and to fine-tune counselling messages in prevention programmes. TRIAL REGISTRATION NUMBER: NCT02459665.

Indexed as

ProbioticsVaginosis, BacterialFemaleHumansInfant, NewbornMaleMedication AdherencePatient Acceptance of Health CarePilot ProjectsRwandaTreatment OutcomeVaginaacceptabilityadherenceAfricabacterial vaginosisvaginal probiotic

Identifiers

PMID32434932
PMCPMC7247375
OpenAlexW3026712574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.